Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
13. September 2021 10:28 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an...
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
07. Juni 2021 08:45 ET
|
Adhera Therapeutics, Inc.
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...
Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors
23. April 2021 09:00 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock
26. September 2019 16:19 ET
|
Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
Adhera Therapeutics Announces Termination of Tender Offer for Warrants
02. Juli 2019 16:15 ET
|
Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer
04. April 2019 09:15 ET
|
Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, April 04, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update
20. November 2018 19:08 ET
|
Adhera Therapeutics, Inc.
Research Triangle Park, NC, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), an emerging specialty pharmaceutical company commercializing therapies that leverage its...
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
09. Oktober 2018 08:00 ET
|
Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...